4/A

PRIMARY DOCUMENT

Company: NRX Pharmaceuticals, Inc.
Filed: June 4, 2021
Period of Report: May 24, 2021
Accession Number: 0001094891-21-000243

View Document ↗ View on SEC.gov ↗